Woynarowska B, Skrincosky D M, Haag A, Sharma M, Matta K, Bernacki R J
Department of Experimental Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263.
J Biol Chem. 1994 Sep 9;269(36):22797-803.
Adhesion of A-121 human ovarian carcinoma cells to extracellular matrix is partly mediated via interaction between galaptin, an endogenous beta-galactoside-binding lectin present in extracellular matrix, and specific cell surface carbohydrate receptors identified as lysosomal associated membrane proteins, lamp-1 and lamp-2. In this study, we report that adhesion of human ovarian carcinoma cells to polystyrene plates coated with polymerized human splenic galaptin can be inhibited by polyclonal antibodies raised against lamp-1 and lamp-2 molecules and by pretreatment of A-121 human ovarian carcinoma cells with glucosamine analogs: 2-acetamido-1,4,6-tri-O-acetyl-3- deoxy-3-fluoro-alpha-D-glucopyranose (3-F-GlcNAc) and 2-acetamido-1,3,6-tri-O-acetyl-4-deoxy-4-fluoro-alpha-D-glucopyranose (4-F-GlcNAc). A 48-h exposure of A-121 cells to individual sugar analogs, or to a combination of the two, resulted in a concentration-dependent inhibition of cellular attachment to polymerized galaptin. Both drugs inhibited glycoprotein biosynthesis as measured by cellular incorporation of labeled [3H]glucosamine and [3H]fucose with negligible effects on [3H]thymidine and [3H]leucine incorporation and cell growth. As a result of drug action on glycoprotein biosynthesis, an alteration in the structure of the galaptin receptor was noted by indirect immunofluorescence and Western blot analysis. Moreover, probing gels of cell extracts with anti-lamp antibodies or Datura stramonium lectin demonstrated significant changes in the reactivity and pattern of glycoprotein staining, suggesting an effect of sugar analogs on the glycosylation of various cellular receptor molecules. The greatest change was observed when tumor cells were exposed to a combination of the two sugar analogs. These studies suggest that specific endogenous lectins and their surface receptors play a role in tumor cell adhesion and perhaps metastasis and may serve as suitable targets for therapeutic exploitation.
A-121人卵巢癌细胞与细胞外基质的黏附部分是通过半乳糖凝集素(一种存在于细胞外基质中的内源性β-半乳糖苷结合凝集素)与特定细胞表面碳水化合物受体(被鉴定为溶酶体相关膜蛋白,即lamp-1和lamp-2)之间的相互作用介导的。在本研究中,我们报告针对lamp-1和lamp-2分子产生的多克隆抗体以及用氨基葡萄糖类似物对A-121人卵巢癌细胞进行预处理,均可抑制人卵巢癌细胞与包被有聚合人脾半乳糖凝集素的聚苯乙烯平板的黏附:2-乙酰氨基-1,4,6-三-O-乙酰基-3-脱氧-3-氟-α-D-吡喃葡萄糖(3-F-GlcNAc)和2-乙酰氨基-1,3,6-三-O-乙酰基-4-脱氧-4-氟-α-D-吡喃葡萄糖(4-F-GlcNAc)。将A-121细胞分别暴露于单个糖类似物或两者的组合48小时,导致细胞对聚合半乳糖凝集素的附着呈浓度依赖性抑制。两种药物均抑制了糖蛋白的生物合成,这通过细胞对标记的[3H]氨基葡萄糖和[3H]岩藻糖的掺入来衡量,而对[3H]胸腺嘧啶和[3H]亮氨酸的掺入以及细胞生长的影响可忽略不计。由于药物对糖蛋白生物合成的作用,通过间接免疫荧光和蛋白质印迹分析发现半乳糖凝集素受体的结构发生了改变。此外,用抗lamp抗体或曼陀罗凝集素探测细胞提取物凝胶,显示糖蛋白染色的反应性和模式有显著变化,表明糖类似物对各种细胞受体分子的糖基化有影响。当肿瘤细胞暴露于两种糖类似物的组合时,观察到的变化最大。这些研究表明,特定的内源性凝集素及其表面受体在肿瘤细胞黏附以及可能的转移中起作用,并且可能成为治疗开发的合适靶点。